Magrilan (Fluoxetine)

Fluoxetine works by blocking the serotonin transporter on presynaptic nerve cells, which prevents the reabsorption of serotonin back into the neuron. This increases the amount of serotonin available in the synaptic gap, enhancing neurotransmission and contributing to mood stabilization and anxiety reduction.

The appropriate dose of Magrilan is determined by a qualified prescriber based on the patient’s specific condition, age, and response to therapy. Dosage adjustments are made according to clinical guidelines and individual tolerability, and patients should follow the prescribing physician’s instructions.

Safety data for fluoxetine during pregnancy are limited, and the drug should only be used if the potential benefits outweigh the risks. Breastfeeding mothers should discuss possible infant exposure with their healthcare provider, as fluoxetine can pass into breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Magrilan (fluoxetine) belongs to the SSRI class, which generally offers a favorable side‑effect profile compared with older tricyclic antidepressants and monoamine oxidase inhibitors. It has a long half‑life, allowing once‑daily dosing, but individual response varies, and clinicians may choose alternative agents based on patient history and tolerability.

Magrilan should be stored below 25 °C in a dry place, kept in its original packaging to protect from moisture and light. Do not store in bathrooms or near heat sources, and keep the product out of reach of children.

Magrilan is taken orally, usually once daily with or without food, as directed by the prescribing clinician. Tablets should be swallowed whole with water; they should not be crushed, chewed, or broken unless specifically instructed by a healthcare professional.

Serious risks include the potential for serotonin syndrome, which can cause high fever, muscle rigidity, and seizures, as well as the emergence of suicidal thoughts, especially in young adults. Other critical concerns are severe allergic reactions, hyponatremia, and cardiac arrhythmias when combined with certain medications.

Magrilan is contraindicated in individuals who have taken monoamine oxidase inhibitors within the past 14 days, those with known hypersensitivity to fluoxetine or any tablet components, and patients with a history of severe cardiac conduction abnormalities when combined with contraindicated drugs.